Author:
Tremblay Nicolas,Park Alex Young,Lamarre Daniel
Reference115 articles.
1. AASLD (2010) Abstracts of the American Association for the Study of Liver Diseases 61st annual meeting and postgraduate course. October 29–November 2, 2010. Boston, Massachusetts, USA. Hepatology 52(Suppl):320A–1291A
2. Annicchiarico BE, Siciliano M, Avolio AW, Caracciolo G, Gasbarrini A, Agnes S, Castagneto M (2008) Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc 40(6):1918–1920. doi: 10.1016/j.transproceed.2008.06.002
3. Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R, Bazzo R (1999) The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289(2):371–384. doi: 10.1006/jmbi.1999.2745
4. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198(6):800–807. doi: 10.1086/591141
5. Beaulieu P, Llinas-Brunet M (2002) Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Anti-Infect Agents 1(2):14. doi: 10.2174/1568012023354983
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献